Files and links (2)
Published VersionCC BY V4.0, Open Access
Journal article
131I-Caerin 1.1 and 131I-Caerin 1.9 for the treatment of non-small-cell lung cancer
Frontiers in Oncology, Vol.12, pp.1-13
2022
Abstract
Objective: To investigate the effect of the 131I-labeled high-affinity peptides Caerin 1.1 and Caerin 1.9 for the treatment of A549 human NSCLC cells.
Methods: ① 3-[4,5-Dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and plate clone formation assays were performed to confirm the in vitro anti-tumor activity of Caerin 1.1 and Caerin 1.9. ② Chloramine-T was used to label Caerin 1.1 and Caerin 1.9 with 131I, and the Cell Counting Kit 8 assay was performed to analyze the inhibitory effect of unlabeled Caerin 1.1, unlabeled Caerin 1.9, 131I-labeled Caerin 1.1, and 131I-labeled Caerin 1.9 on the proliferation of NSCLC cells. An A549 NSCLC nude mouse model was established to investigate the in vivo anti-tumor activity of unlabeled Caerin 1.1, unlabeled Caerin 1.9, 131I-labeled Caerin 1.1, and 131I-labeled Caerin 1.9.
Results: ① Caerin 1.1 and Caerin 1.9 inhibited the proliferation of NSCLC cells in vitro in a concentration-dependent manner. The half-maximal inhibitory concentration was 16.26 µg/ml and 17.46 µg/ml, respectively, with no significant intergroup difference (P>0.05). ② 131I-labeled Caerin 1.1 and 131I-labeled Caerin 1.9 were equally effective and were superior to their unlabeled versions in their ability to inhibit the proliferation and growth of NSCLC cells (P>0.05).
Conclusions: 131I-labeled Caerin 1.1 and 131I-labeled Caerin 1.9 inhibit the proliferation and growth of NSCLC cells and may become potential treatments for NSCLC.
Details
- Title
- 131I-Caerin 1.1 and 131I-Caerin 1.9 for the treatment of non-small-cell lung cancer
- Authors
- Na Liu (Author) - First Affiliated Hospital of Guangzhou University of Chinese MedicineTiantian He (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityZewei Xiao (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityJuan Du (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityKeke Zhu (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityXiongying Liu (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityTongsheng Chen (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityWenjuan Liu (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuoying Ni (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityXiaosong Liu (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityTianfang Wang (Author) - University of the Sunshine Coast, Queensland, GeneCology Research Centre - LegacyJiangtao Quan (Author) - General Hospital of the Southern Theatre Command (China)Jinhe Zhang (Corresponding Author) - General Hospital of the Southern Theatre Command (China)Peipei Zhang (Corresponding Author) - First People's Hospital of FoshanJianwei Yuan (Corresponding Author) - First Affiliated Hospital of Guangdong Pharmaceutical University
- Publication details
- Frontiers in Oncology, Vol.12, pp.1-13
- Publisher
- Frontiers Research Foundation
- Date published
- 2022
- DOI
- 10.3389/fonc.2022.861206
- ISSN
- 2234-943X
- Copyright note
- © 2022 Liu, He, Xiao, Du, Zhu, Liu, Chen, Liu, Ni, Liu, Wang, Quan, Zhang, Zhang and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Organisation Unit
- School of Science and Engineering - Legacy; University of the Sunshine Coast, Queensland; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99664998902621
- Output Type
- Journal article
Metrics
34 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Oncology
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites